Business Segments · Gain on litigation settlement
Business Segments — Gain on litigation settlement
Roivant Sciences Business Segments — Gain on litigation settlement remained flat by 0.0% to $192.56M in Q1 2026 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryOther
SignalHigher is better
VolatilityVolatile
First reportedQ2 2023
Last reportedQ1 2026
How to read this metric
An increase represents a significant one-time cash inflow that improves liquidity but does not reflect sustainable business growth.
Detailed definition
This represents non-recurring income recognized from the successful resolution of legal disputes or patent litigation. I...
Peer comparison
Similar to 'legal settlements' or 'litigation recoveries' reported by other pharmaceutical companies protecting their patent portfolios.
Metric ID:
roiv_segment_reportable_segment_gain_on_litigation_settlementHistorical Data
3 years
| FY'23 | FY'24 | FY'25 | |
|---|---|---|---|
| Value | $0.00 | $0.00 | $770.24M |
Range$0.00 – $770.24M
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Roivant Sciences's business segments — gain on litigation settlement?
- Roivant Sciences (ROIV) reported business segments — gain on litigation settlement of $192.56M in Q1 2026.
- What does business segments — gain on litigation settlement mean?
- One-time financial gains resulting from the successful settlement of legal disputes.